While GPR161 has been reported to drive oncogenic programs in breast cancer [66], it acts as a negative regulator of the HH pathway in medulloblastoma (MB), where GPR161 negatively influences MB progenitor proliferation [66,67]. This evidence concerns the gene GPR161 and breast carcinoma.